Drug interactions between Aptivus and zidovudine
| Results for the following 2 drugs: |
|---|
| Aptivus (tipranavir) |
| zidovudine |
Interactions between your selected drugs
zidovudine ↔ tipranavir
Applies to:zidovudine and Aptivus (tipranavir)
MONITOR: Coadministration with tipranavir in combination with low-dose ritonavir may decrease the plasma concentrations of zidovudine. The mechanism of interaction is unknown. In 102 HIV-positive subjects, three different regimens of tipranavir/ritonavir (250 mg/200 mg; 750 mg/100 mg; and 1250 mg/100 mg twice a day for 21 days) decreased the mean peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) of steady-state zidovudine (300 mg twice a day) by approximately 50% and 35%, respectively, compared to administration of zidovudine without tipranavir/ritonavir. In 54 healthy volunteers, tipranavir/ritonavir (500 mg/100 mg and 750 mg/200 mg twice a day for 12 days) reduced the Cmax and AUC of zidovudine (300 mg single dose) by approximately 60% and 40%, respectively. The clinical significance of these changes is unknown. Zidovudine had negligible effects on the pharmacokinetics of tipranavir.
MANAGEMENT: Antiretroviral response should be monitored closely when tipranavir/ritonavir is used in combination with zidovudine. Currently, there are no dosage adjustment recommendations available for zidovudine when prescribed with tipranavir/ritonavir.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
